Work

Use of Neoflorum probiotic to prevent gastrointestinal tract damage during antibiotic therapy in children

Year: 2024
Type: article
Abstract: The use of antibiotics can affect the resistance of the intestinal microflora, causing digestive disorders and antibiotic-associated diarrhea (AAD). The drug "Neoflorum", which contains Lactobacillus rhamnosus and Saccharomyces boulardii, is a promising combined probiotic for maintaining the health of the intestinal microflora. The aim of the study is to investigate the effectiveness of the probiotic "Neoflorum" in the prevention of AAD and the safety of the use in children, who are receiving antibiotics because of acute respiratory infection (ARI). Materials and methods. An open, prospective, non-interventional, comparative study was conducted. 47 children aged 3-13 were examined (average age 6.91±2.87 years). The main group of the study included 25 children who received an antibiotic and a combined probiotic "Neoflorum" in the complex treatment of an ARI. 22 children of control group received an antibiotic without a probiotic. Results. At the beginning of the study, none of the patients in both groups complained of dyspeptic disorders. Analysis of coprological studies and the level of fecal calprotectin in both groups at the initial stage of treatment did not reveal any pathological changes. AAD developed in 20% of children in the intervention group and 45.5% of children in the control group, which was 2.3 times less. The level of fecal calprotectin was normal in almost all children with AAD (except one child of the control group) on the first day of the diarrhea. 92% of children in the main group noted good tolerance of "Neoflorum", and two children - satisfactory tolerance. There were no side effects while taking "Neoflorum". Conclusions. In the case of conducting oral antibacterial therapy against the background of the use of the probiotic Neoflorum AAD from the first day of treatment, AAD was detected 2.3 times less often than when conducting antibiotic therapy without the background intake of a probiotic. The use of the Neoflorum probiotic from the first day of antibiotic therapy made it possible to achieve a statistically significant antidiarrheal effect already on the 4-5th day, as indicated by a significantly lower number of children with AAD in the main group - 16% compared to the control group - 45.5%. Good tolerance of "Neoflorum" is noted by 92% of patients. The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the clinical base. The informed consent of the patient was obtained for conducting the studies. No conflict of interests was declared by the authors.
Language: English
Subfield: Food Science
Open Access status: diamond
OpenAlex ID: W4400604635
FWCI: 0.164
Cites: 30
Cited by: 1
Related to: 10